Second, parallel 4T1‐targeting ability with PCM@NP was demonstrated in anti‐CD47‐PCM@NP, which was 3.9‐fold superior to NP, demonstrating the inherited tumor‐homing function from the parent cell membrane (Figure 2C and Figure S8B, Supporting Information), and the precisely on‐demand antibody release was subsequently validated using 4T1 homologous cell line with low CD47 expression (CD47−/− 4T1) as nontarget control (Figure S9, Supporting Information). The gene discussed is CD47; the disease is neoplasm.